REAL-WORLD COSTS AND HEALTHCARE RESOURCE UTILIZATION (HRU) PATTERNS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R-MCL) PATIENTS POST-IBRUTINIB FAILURE

被引：0
|
作者：
Lam, J. [1 ]
Lin, V. W. [2 ]
Purdum, A. G. [2 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
[2] Kite, Santa Monica, CA USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.227
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN103
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [31] Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel): A summary of real-world evidence.
    Yang, Hongbo
    Qi, Cynthia Zhengyun
    Dalal, Anand
    Bollu, Vamsi
    Zhang, Jie
    Zhang, Su
    Lim, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)
    Dreyling, M.
    Phillips, T.
    Dickinson, M.
    Morschhauser, F.
    Bachy, E.
    Crump, M.
    Trneny, M.
    Bartlett, N. L.
    Zaucha, J.
    Wrobel, T.
    Offner, F.
    Humphrey, K.
    Lundberg, L.
    Relf, J.
    de L'Etang, Filezac A.
    Carlile, D.
    Byrne, B.
    Qayum, N.
    Carlo-Stella, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 23 - 24
  • [33] Clinical Efficacy of the Rivbd Combination for Refractory/Relapsed (R/R) Mantle Cell Lymphoma (MCL) Patients: A Retrospective Study of the French Lysa Group
    Regny, Caroline
    Malak, Sandra
    Manson, Guillaume
    Sarkozy, Clementine
    Clavert, Aline
    Herbaux, Charles
    Chauchet, Adrien
    Jourdan, Eric
    Sanhes, Laurence
    Godmer, Pascal
    Pascal, Laurent
    Le Du, Katell
    Sutton, Laurent
    Voillat, Laurent
    Dupuis, Jehan
    Anglaret, Bruno
    Gressin, Remy
    BLOOD, 2016, 128 (22)
  • [34] REAL-WORLD CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS IN US PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)
    Nicacio, L. Viana
    Calkins, G.
    Curtis, M.
    Kohansimeh, J.
    Lindberg, F. P.
    Larrabee, K.
    Jaskiw, A.
    Feinstein, R. N.
    Terry, M.
    Plotkin, L.
    Palladino, M. L.
    Krishna, A.
    Green, R. J.
    HAEMATOLOGICA, 2015, 100 : 742 - 742
  • [35] EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL)
    Balasubramanian, N.
    Cummings, J.
    Lin, H.
    Raviele, A.
    Peng, L.
    Omidpanah, A.
    Espinola, R.
    Kostic, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S54 - S54
  • [36] Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany
    Steinmetz, Tilman Hans
    Singh, Moushmi
    Lebioda, Andrea
    Fink, Leah
    Schoehl, Martina
    Rieth, Achim
    Gonzalez-McQuire, Sebastian
    Engelhardt, Monika
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 114 - 122
  • [37] CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A 'Real-World' Analysis of Patterns of Failure and Role of Bridging Therapy
    Ravella, Revathi
    Zhang-Velten, Elizabeth Ren
    Awan, Farrukh T.
    Rizvi, Syed M.
    Shah, Jennifer L.
    Desai, Neil B.
    Geethakumari, Praveen Ramakrishnan
    Kumar, Kiran A.
    BLOOD, 2020, 136
  • [38] Real-world healthcare costs and resource utilization (HRU) among patients treated with erenumab in the United States: A retrospective claims database study
    Tepper, S. J.
    Schwedt, T. J.
    Vo, P.
    Joshi, P.
    Glassberg, M.
    Abdrabboh, A.
    Ferraris, M.
    Tiwari, S.
    Thompson, J.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 17 - 18
  • [39] Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).
    Huynh, Lynn
    Cai, Beilei
    Sharperson, Camara
    Lejeune, Dominique
    Duh, Mei Sheng
    Kim, Michelle Kang
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [40] Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and Lanreotide for the treatment of neuroendocrine tumors (NET)
    Lynn Huynh
    Cai, Beilei
    Lejeune, Dominique
    Cheng, Mu
    Lax, Angie
    Duh, Mei S.
    Cheng, Wendy
    Kim, Michelle K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 134 - 134
12345